About Skymap Pharmaceuticals Private Limited
Data last updated:
Skymap Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 June 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24233DL2006PTC150088. Its GSTIN is 05AACCG7356C1ZV (Uttarakhand). The company holds 5 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹6.5 Cr and a paid-up capital of ₹50 Lakh. It was formerly known as Skymap Pharma Private Limited and Gsk Pharmaceuticals Private Limited. It is led by directors including Vinod Kumar Gupta and Sanjay Gupta.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 302 Narmada Block – 5 Pocket D – 6 Vasant Kunj, New Delhi, Delhi, India – 110070.
As per the financials filed for FY 2025, the company reported a revenue of ₹409.08 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹14.53 Cr (net margin 3.6%) and EBITDA of ₹34.36 Cr (EBITDA margin 8.4%). Revenue has grown at a compounded annual rate (CAGR) of 3% over three years and 8% over five years.
The company has about 314 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Skymap. As per MCA filings, the company has open charges of ₹415.32 Cr and satisfied charges of ₹292.84 Cr on record. Court records list 60 cases involving the company, including 21 filed by the company and 39 filed against it; 12 cases are pending. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹49 Lakh; the latest was in May 2020. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Aspiro Pharma Limited with revenue of ₹418.29 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2020, listing 992 overdue payments to 77 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website skymap.in.
Company details
Name history
Skymap Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Skymap Pharma Private Limited, and Gsk Pharmaceuticals Private Limited.. The current legal name is Skymap Pharmaceuticals Private Limited.
| Company Name | Status |
|---|---|
| Skymap Pharmaceuticals Private Limited | Current |
| Skymap Pharma Private Limited | Previous |
| Gsk Pharmaceuticals Private Limited. | Previous |
Contact details
Skymap Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is skymap.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address302 Narmada Block – 5 Pocket D – 6 Vasant Kunj, New Delhi, Delhi, India – 110070
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Skymap Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Skymap Pharmaceuticals are manufacturing and support service to organizations. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and other support services to organizations. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| N | Support service to Organizations | N7 | Other support services to organizations |
To see the full business activity and turnover split of Skymap Pharmaceuticals Private Limited, buy the company report.
Financials of Skymap Pharmaceuticals Private Limited
FY 2025 filings availableSkymap Pharmaceuticals Private Limited reported revenue of ₹409.08 Cr (up 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 2% growth in the latest year. EBITDA fell 23% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹409.08 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹34.36 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹14.53 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.4% | ||||
| Net Profit Margin | 3.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Skymap Pharmaceuticals Private Limited, buy the company report.
Board of directors of Skymap Pharmaceuticals Private Limited
Skymap Pharmaceuticals has 3 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vinod Kumar Gupta Also directs: Datt Infrastructure and Services Private Limited | Director | 12 Oct 2017 | 9 Years 0 Months | Current |
| Sanjay Gupta Also directs: MKS Healthcare Private Limited, Cosmax Pharma Private Limited, Skymap Packaging Private Limited and 5 more | Director | 24 Jun 2006 | 20 Years 4 Months | Current |
| Manish Garg Also directs: Cosmax Pharma Private Limited, Glensmith Labs Private Limited, Nortis Lifesciences Private Limited and 1 more | Director | 29 Sep 2015 | 11 Years 1 Months | Current |
Peer comparison
Skymap Pharmaceuticals Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aspiro Pharma Limited | ₹418.29 Cr (FY 2025) | 147.0% | Markook, Telangana, India | |||
| Scott-Edil Advance Research Laboratories & Education Limited | ₹418.23 Cr (FY 2025) | 17.0% | Chandigarh, India | |||
| Senores Pharmaceuticals Limited | ₹417.51 Cr (FY 2025) | 92.0% | Ahmedabad, Gujarat, India | |||
| Visa Drugs & Pharmaceuticals Private Limited | ₹414.04 Cr (FY 2016) | 32.0% | Kolkata, West Bengal, India | |||
| Themis Medicare Limited | ₹410.18 Cr (FY 2025) | 6.0% | Vapi, Gujarat, India | |||
| Skymap Pharmaceuticals Private Limitedthis company | ₹409.08 Cr (FY 2025) | ₹14.53 Cr | 3.6% | 2.0% | 314 | New Delhi, Delhi, India |
| Arene Life Sciences (Unit 4) Private Limited | ₹405.87 Cr (FY 2021) | 3.0% | Hyderabad, Telangana, India | |||
| United Biotech Private Limited | ₹404.94 Cr (FY 2024) | 27.0% | New Delhi, Delhi, India | |||
| Torque Pharmaceuticals Private Limited | ₹404.13 Cr (FY 2024) | 1.0% | Chandigarh, India | |||
| Steril-Gene Life Sciences Private Limited | ₹404.06 Cr (FY 2025) | 41.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Skymap Pharmaceuticals Private Limited, buy the company report.
Auditor
Skymap Pharmaceuticals Private Limited is audited by Singla Tayal & Co for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Singla Tayal & Co | FY 2024 | 000882N |
Shareholding
The shareholding of Skymap Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Skymap Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Mar 2020 | 100334043 | Hdfc Bank Limited | ₹95 Lakh | Open | |
| 02 Aug 2018 | 100206277 | Hdfc Bank Limited | ₹337.09 Cr | Open | |
| 02 Jul 2015 | 10587853 | Hdfc Bank Limited | ₹77.29 Cr | Open | |
| 23 Jul 2019 | 100283867 | Citi Bank N.A. | ₹8 Cr | Satisfied | |
| 26 May 2017 | 100114747 | Hdfc Bank Limited | ₹284.84 Cr | Satisfied |
To see the full charge records of Skymap Pharmaceuticals Private Limited, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Skymap Pharmaceuticals Private Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹49 Lakh; the latest was in May 2020.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Apr 2015 | Funding round | ₹49 Lakh | Investors: 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Skymap Pharmaceuticals Private Limited has 60 court cases on record: 21 filed by Skymap Pharmaceuticals, 39 filed against it. 12 cases are pending and 48 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 40 | 33 | 10 |
| High courts | 19 | 5 | 2 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 60)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (LPETN) | Filed against the company by Maneesh Pharmaceuticals Ltd. | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Cedar Properties & Trading LLP & Ors. | Disposed |
| District court, Faridabad, Haryana | Cheque dishonour complaint | Filed by the company against Life Line Biotech Ltd | Disposed |
| High Court of Delhi | Court case (CO.PET.) | Filed by the company against Life Line Biotech Limited | Disposed |
| Bombay High Court | Court case (S) | Filed against the company by Maneesh Pharmaceuticals Ltd. | Disposed |
To see the full case history of Skymap Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Skymap Pharmaceuticals Private Limited has 4 MSME Form 1 returns on record between 2019 and 2020, listing 992 overdue payments to 77 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 77)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Chemsynth Labs | |||
| Wang Pharmaceuticals & Chemicals | |||
| an individual supplier | |||
| Jamnadas Industries | |||
| Arvind Pharma Chem Private Limited |
To see the full MSME payment records of Skymap Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Skymap Pharmaceuticals has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Skymap Lifesciences Private Limited | U24230DL2022PTC408893 | |
| Torrvis Lifesciences Private Limited | U24290DL2023PTC409529 |
To see the full group structure of Skymap Pharmaceuticals Private Limited, buy the company report.
Employees & EPFO
Skymap Pharmaceuticals Private Limited has a workforce of 314 employees on its EPFO records as of Apr 01, 2024, across 1 active EPFO establishment.
GST
Skymap Pharmaceuticals has 5 GST registrations: 2 active and 3 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AACCG7356C1ZV | Uttarakhand | Active | 01 Jul 2017 |
| 06AACCG7356C1ZT | Haryana | Active | 08 Feb 2020 |
To see the full GST registrations and return filing status of Skymap Pharmaceuticals Private Limited, buy the company report.
Recent activity
Skymap Pharmaceuticals Private Limited has 5 board changes on record since 2006: 3 appointments and 2 cessations. The latest: Vinod Kumar Gupta was appointed as Director on 12 Oct 2017.
6 earlier events are in the company report.
Frequently asked questions
Skymap Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 June 2006 (20+ years old) and is registered under CIN U24233DL2006PTC150088.
Skymap Pharmaceuticals has 3 current directors:
- Vinod Kumar Gupta - Director
- Sanjay Gupta - Director
- Manish Garg - Director
The latest financial statements of Skymap Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Skymap Pharmaceuticals is 05AACCG7356C1ZV, registered in Uttarakhand. The company has 5 GST registrations in all, of which 2 are active and 3 are cancelled or inactive. Other active GSTINs include 06AACCG7356C1ZT (Haryana).
The CIN (Corporate Identification Number) of Skymap Pharmaceuticals is U24233DL2006PTC150088. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Skymap Pharmaceuticals has 60 court cases on record: 21 filed by the company and 39 filed against it. 12 are pending. Most are in the district courts.
Skymap Pharmaceuticals was incorporated on 24 June 2006, making it 20+ years old. It is registered with the Registrar of Companies, Delhi.
Skymap Pharmaceuticals has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹49 Lakh; the latest was in May 2020.
The peers of Skymap Pharmaceuticals by revenue are Aspiro Pharma Limited, Scott-Edil Advance Research Laboratories & Education Limited, Senores Pharmaceuticals Limited, Visa Drugs & Pharmaceuticals Private Limited, Themis Medicare Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Vinod Kumar Gupta was appointed as Director on 12 Oct 2017. Kishori Lal Gupta ceased to be Director on 09 Oct 2016. Manish Garg ceased to be Additional Director on 30 Sep 2015. Skymap Pharmaceuticals has 5 board changes on record in total.
Skymap Pharmaceuticals has 4 MSME Form 1 returns on record between 2019 and 2020, listing 992 overdue payments to 77 micro and small suppliers. The latest return was filed on 10 Sep 2020.
Skymap Pharmaceuticals can be reached through the website skymap.in. Its registered office is in New Delhi, Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
